skip to content
CMS Buy Now
Detailed Quote
5i Report
Rating
B+

Review of Knight Therapeutics

SEP 19, 2018 - Specialty Pharmaceutical company focused on later stage commercialization of drugs. The company continues to hold on to a high balance of cash, waiting for the right opportunity. Despite strong fundamentals and management, the increased opportunity cost and stock trading sideways justify the rating to be downgraded one notch to 'B+'.

Download Report
Company Profile
Interactive Chart
Key Ratios
Top Banner 5i Free Trial
Earnings
Analyst Recommendations
5i Recent Questions

Q: Looking at the BE portfolio, which are the 4-5 companies with the best balanced sheets?

Read Answer Asked by Christian on August 19, 2019

Q: Is the recent marginal and probably temporary rise in Knight's share price due to the surprise revelation that the Company had purchased over 4.5 million shares under the 12.5 million repurchase program within about a month from the start date? It's a bit ironic that Medison's meddling has caused the share price to flatline which helped Knight by allowing them to buy cheap stock! Go Meir...

Read Answer Asked by Steven on August 14, 2019
Insiders
5i Free Trial 300x250
Share Information
News and Media